Researchers from Monash University have developed a new drug delivery strategy able to block pain within the nerve cells, in what could be a major development of an immediate and long lasting treatment for pain.
More than 100 million Americans suffer from chronic pain and this figure is expected to grow, driven by the increased life expectancy, increasing incidence of diabetes and cancer, combined with better survival rates, often leaving patients with severe and poorly treated pain. The global market for nerve pain treatments is over US$600 billion and yet current pain therapies are not completely effective and often suffer from unwanted side effects.
Research published in the journal, Science Translational Medicine, reveals how a target protein, long known to be associated with both chronic and acute pain, works within the nerve cell. This protein is the NK1 receptor, the receptor of the neuropeptide substance P, which mediates pain transmission. Because of its association with pain and other diseases of the nervous system, many drug development attempts have focused on inhibiting this receptor, but the efficacy of these treatments has been very limited. This new work shows that such ineffectiveness could be in part because the treatments targeted the protein on the surface of the nerve cell.
Dr Michelle Halls and Dr Meritxell Canals from the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre for Excellence in Bio-Nano Science (CBNS) at Monash University, have worked with Professor Nigel Bunnett, previously at Monash and now at Columbia University in the US, and Professor Chris Porter from MIPS and CBNS.
Together they have found that the NK-1 receptor controls pain once it is inside the cell — so drugs that merely block it when it is on the surface of the cell have little efficacy. Instead, this new research shows that, in animal models, if the NK-1 receptor is blocked once it enters the nerve cell, it is possible to suppress pain more effectively.
Dr Halls said that the new strategy of “targeting receptors inside the cell represents a new frontier in drug delivery and a novel therapeutic strategy for dealing with pain.”
Working with a multidisciplinary team of cell biologists, pharmacologists, physiologists and drug delivery experts, the researchers developed drugs that specifically target NK-1 receptors within the nerve cell. Animal studies showed that using the drugs — which have an engineered lipid attachment that targets the drug to the NK-1 receptor inside the cell, could block pain for extended periods in several animal models.
Dr Canals said: “This is a proof-of-concept study that shows that we can re-engineer current pain drugs and make them more effective. The challenge is now to translate the technology into human clinical trials. This is a complex and challenging path — but the ultimate benefits to patients with nerve pain are potentially highly significant.”
The Latest on: Pain relief
- Why Do I Have Recurring Back Pain and Diarrhea? on September 18, 2018 at 11:56 am
Some people have an appendix that extends behind the colon, which may cause lower back pain. Appendicitis needs immediate treatment. Left untreated, your condition can worsen dramatically in just a ma... […]
- Hisamitsu intros larger Salonpas Pain Relief Patch on September 18, 2018 at 8:53 am
Hisamitsu America, the parent company of Salonpas, has unveiled the line’s latest addition. The Florham Park, N.J.-based company has launched the new Salonpas Pain Relief Patch Large, which comes in a ... […]
- Camurus pain relief candidate CAM2038 successful in late-stage low back pain study on September 18, 2018 at 7:58 am
A Phase 3 clinical trial evaluating Camurus' (OTC:CAMRF) long-acting CAM2038 (buprenorphine) in opioid-experienced patients with chronic low back pain met the primary and secondary endpoints ... […]
- Animal rescue group plans Hurricane Florence relief trip on September 17, 2018 at 5:36 pm
N.C. "We're looking to bring relief," said Erica Mehnken, co-founder of No More Pain Rescue. "We're renting vans; we have donation lists for both animals and people," Mehnken said. "We're going to bri... […]
- Healthcare Facilities Discover Pain Relief For the Datacenter on September 17, 2018 at 4:58 pm
People who work at healthcare facilities suffer from pains of their own, and the source of the pain may surprise you. It is kind of pain has nothing to do with the human body, and the relief cannot co... […]
via Google News and Bing News